APA (7th ed.) Citation

Yuling Zhou, M., Liang Zeng, M., Nong Yang, M., & Yongchang Zhang, M. (2020, June). Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation−Mediated Erlotinib Resistance After Failure of Chemotherapy. JTO Clinical and Research Reports.

Chicago Style (17th ed.) Citation

Yuling Zhou, MS, MS Liang Zeng, MS Nong Yang, and MD Yongchang Zhang. "Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a Patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation−Mediated Erlotinib Resistance After Failure of Chemotherapy." JTO Clinical and Research Reports Jun. 2020.

MLA (9th ed.) Citation

Yuling Zhou, MS, et al. "Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a Patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation−Mediated Erlotinib Resistance After Failure of Chemotherapy." JTO Clinical and Research Reports, Jun. 2020.